药明康德

“When we see that promising pipelines cannot reach patients as quickly as possible because of capacity constraints, capacity is no longer just ‘infrastructure’—it is an important link to patients. That is why we are accelerating the build‑out of our capabilities and capacity scale to respond to our clients’ needs.” Our new drug product facility in Delaware is the manifestation of our commitment to enabling our global partners to bring necessary treatments to patients worldwide. Read more: https://lnkd.in/g3D453pQ

From posing critical questions at the bench to steering business development initiatives, Jacob Mandell, M.S. embodies the spirit of innovation. As he marks his 5th year with WuXi AppTec, he reflects on a journey that began with a simple question: What happens after discovery? Jacob's story is a testament to how progress is built on self-motivation, collective effort, and the strength of our community. At WuXi AppTec, we are proud to see more possibilities realized in people like Jacob who value the shared vision that every drug can be made, and every disease can be treated, which drives our work and fuels our commitment to innovation. Join us in celebrating Jacob’s journey and our shared mission. #WuXiAppTec #HealthcareInnovation #BusinessDevelopment #Collaboration #ScientificDiscovery Read Jacob's full story: https://lnkd.in/eHyGfw9Q

As oncology drug discovery becomes increasingly modality-rich and biologically complex, one question is more important than ever: How do you match the right target, modality, assay strategy, and patient population to maximize the probability of success? In our latest article, inspired by the expert panel discussion at the WuXi AppTec Spring Science Forum, we explore how the oncology landscape is evolving beyond traditional small molecules and monoclonal antibodies toward a broader therapeutic toolbox that now includes: 🔹 Protein degraders and molecular glues 🔹 ADCs and multispecific antibodies 🔹 Radioligands, peptides, and macrocycles Our experts discuss how today’s oncology programs increasingly require a systems-level understanding of cancer biology, disciplined modality selection, and integrated decision-making across biology, chemistry, assay strategy, DMPK, formulation, and development planning. WuXi AppTec’s integrated CRDMO platform can help innovators navigate this growing complexity by connecting discovery biology, medicinal chemistry, screening technologies, assay development, DMPK, formulation, and development expertise within a unified framework. By integrating these capabilities early, teams can make more informed decisions, reduce technical uncertainty, and accelerate the path from target hypothesis to high-quality development candidates. Click 👇 to access the full article: https://lnkd.in/e2yXwqpp #Oncology #DrugDiscovery #CRDMO #TargetedProteinDegradation #PROTAC #MolecularGlue #ADC #PrecisionMedicine #Biotech #DrugDevelopment

WuXi AppTec has been named a constituent of the FTSE4Good Index Series for the fourth consecutive year, achieving the highest score of 5 points in Corporate Governance, Anti-Corruption, and Labor Standards. The FTSE4Good recognizes companies demonstrating strong sustainability and responsible business practices relative to their peers. It does this through independent assessments that look at what companies actually do: how they’re governed, how they treat their people, how they operate 24/7. WuXi AppTec’s inclusion in the index across four consecutive assessments reflects our teams’ continued commitment to responsible business practices every day — not just at reporting time. Read the full announcement: https://lnkd.in/exBd2475

As therapeutic modalities continue to expand beyond small molecules and monoclonal antibodies, one principle is becoming increasingly important in drug discovery: modality should follow biology. At the recent WuXi AppTec Spring Science Forum in Cambridge, industry experts explored how researchers can build greater translational confidence as they advance emerging modalities — from ADCs and bispecific antibodies to peptides, oligonucleotides, and protein degraders. The discussion highlighted several key themes: 🔹 Using fit-for-purpose models to probe biology 🔹 Generating clinically relevant translational evidence early 🔹 Leveraging modalities not only as therapies, but also as biological tools 🔹 Addressing IND-enabling challenges for emerging modalities In our latest article, we explore how a biology-first framework can help innovators strengthen decision-making, improve translational relevance, and support more informed paths toward clinical development. Read the full article here 👇 https://lnkd.in/e2taCt87 #DrugDiscovery #Biotech #TranslationalResearch #ADC #BispecificAntibodies #Oligonucleotides #ProteinDegradation #DrugDevelopment #CRDMO

As drug candidates grow more complex, pharmaceutical manufacturing is facing a new constraint: not whether a molecule can be made, but how efficiently it can be produced at scale without compromising the environment. That shift moves the focus from process efficiency alone to placing sustainability at the heart of strategy. That’s where green chemistry matters. On World Environment Day, Dr. Xiaoyong Fu, Executive Vice President of WuXi AppTec and Head of WuXi STA, shares how green chemistry is reshaping pharmaceutical manufacturing through technologies including biocatalysis and continuous manufacturing. By integrating these innovations into our #CRDMO platform, WuXi AppTec is helping global partners reduce waste, cut solvent use, and accelerate development timelines, driving greater value to both the industry and the environment.   Read more: https://lnkd.in/gB-yCs8F #WorldEnvironmentDay #GreenChemistry #Biocatalysis #ContinuousManufacturing #Sustainability

How can Europe accelerate innovation and strengthen its position as a global hub for life sciences? Join us at bio:cap from June 9-11, 2026, in Berlin, where our Co-CEO Dr. Steve Yang will share his perspective on June 9 at 4:45 PM. Innovation thrives through collaboration. As scientific discoveries continue to advance at a rapid speed, building strong partnerships across the biopharmaceutical ecosystem is critical to transforming ideas into therapies that improve patients’ lives. We look forward to connecting with industry leaders, innovators, and partners to discuss the opportunities shaping the future of healthcare and biopharmaceutical innovation in Europe. Explore the full program: https://lnkd.in/dZBuWhnS #biocap #Biotech #LifeSciences #Innovation #HealthcareInnovation #WuXiAppTec

In our latest article, we present a case study in which a client urgently required the construction of a precise three-dimensional molecular scaffold with the correct stereochemical configuration to build a biologically active molecule. The project faced several intertwined challenges, including low yield, poor cis-trans selectivity, and difficulties in scaling up the batch process. To address these challenges, WuXi AppTec’s Research Chemistry Services (RCS) team turned to photochemistry. Applying photochemistry in an industrial setting demands highly specialized equipment and expertise, requiring light energy to penetrate the reaction system uniformly and stably — a feat nearly impossible in traditional reaction vessels. Integrating high-throughput experimentation (HTE) and flow chemistry can help address this challenge. Click 👇 to learn more. https://lnkd.in/ePCCXtKm #Photochemistry #DiscoveryChemistry #FlowChemistry #HTE #SpecialtyChemistry

With the widespread adoption of LED technology, advances in photocatalytic methodologies, and the evolution of flow chemistry, photochemistry has transformed from a niche method into a powerful tool in modern drug discovery. For certain types of molecules, photocatalysis offers a synthetic route that may be more efficient or, in some cases, not readily achievable with conventional methods. With its mild, rapid, and heating-free characteristics, photocatalysis offers new pathways for synthesizing complex molecules such as targeted protein degraders (TPDs). By integrating high-throughput experimentation (HTE) and flow chemistry, WuXi AppTec’s chemistry platform continues to expand the scope of scalable photochemical processes. Our capabilities support client programs from early condition screening and parameter optimization through process stabilization and flow scale-up, enabling production from hundreds of grams to kilogram scale. Click 👇 to read our latest case study to learn how advanced photochemistry strategies can help accelerate complex molecule synthesis: https://lnkd.in/epKCVECT #Photochemistry #DiscoveryChemistry #FlowChemistry #HTE #TPD #ProteinDegraders #SpecialtyChemistry